{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:28Z","timestamp":1789656028402,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011943","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T00:00:00Z","timestamp":1527292800000}}],"reference-count":109,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011943.pub2","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T12:47:01Z","timestamp":1527338821000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mirtazapine adjunct for people with schizophrenia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Luke A","family":"Perry","sequence":"first","affiliation":[{"name":"Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvesh","family":"Ramson","sequence":"additional","affiliation":[{"name":"Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Stricklin","sequence":"additional","affiliation":[{"name":"Miami University; Nursing; 1601 University Blvd Hamilton USA 45011"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,26]]},"reference":[{"issue":"2-3","key":"10.1002\/14651858.CD011943.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2009.11.008","article-title":"The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial","volume":"116","author":"Abbasi","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD011943.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004850-200103000-00003","article-title":"Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study","volume":"16","author":"Berk","year":"2001","journal-title":"Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0003|cit3","unstructured":"Berk M Ichim C Brook S Mirtazepine treatment of negative schizophrenia Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0004|cit4","unstructured":"Berk M Ichim C Brook S Mirtazepine treatment of negative schizophrenia Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011943.pub2-BIB0005|cit5","first-page":"S112","article-title":"Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol","volume":"3","author":"Ichim","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011943.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.1017","article-title":"Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial","volume":"24","author":"Berk","year":"2009","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0008|cit7","unstructured":"Dodd S Mirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: a double-blind, randomised, placebo controlled trial Australian New Zealand Clinical Trials Registry 2004"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011943.pub2-BIB0007|cit8","first-page":"139","article-title":"Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial","volume":"11","author":"Dodd","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0009|cit9","unstructured":"Bertolino A Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory Stanley Foundation Research Programs 2002"},{"issue":"6","key":"10.1002\/14651858.CD011943.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/JCP.0b013e3182a4ec77","article-title":"Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia","volume":"33","author":"Caforio","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pnpbp.2010.11.006","article-title":"Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial","volume":"35","author":"Cho","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011943.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.9758\/cpn.2011.9.2.73","article-title":"The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo-controlled trial","volume":"9","author":"Lee","year":"2011","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0013|cit13","unstructured":"Lee SH Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial www.controlled-trials.com 2009"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0016|cit14","unstructured":"Poyurovsky M Mirtazapine for bipolar disorder and schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"Suppl. 3","key":"10.1002\/14651858.CD011943.pub2-BIB0014|cit15","first-page":"S299","article-title":"Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study","volume":"12","author":"Poyurovsky","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011943.pub2-BIB0015|cit16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.jcp.0000084027.22282.16","article-title":"Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study","volume":"23","author":"Poyurovsky","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011943.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.biopsych.2005.12.007","article-title":"Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial","volume":"59","author":"Poyurovsky","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0019|cit18","unstructured":"Joffe G Efficacy of add-on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double-blind, placebo-controlled trial with an open-label extension phase isrctn.com\/ISRCTN00721331"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0020|cit19","unstructured":"Joffe G Mirtazapine for schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"1-3","key":"10.1002\/14651858.CD011943.pub2-BIB0018|cit20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.schres.2008.12.002","article-title":"Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial","volume":"108","author":"Joffe","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuropharm.2012.06.028","article-title":"Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia - a path model investigation","volume":"64","author":"Stenberg","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Stenberg J-H Terevnikov V Joffe M Tiihonen J Tchoukhine E Burkin M Effects of add-on mirtazapine on neurocognition in schizophrenia -a double-blind, randomized, placebo-controlled study Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain 2009","DOI":"10.1017\/S1461145709990897"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.pnpbp.2011.03.004","article-title":"More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia","volume":"35","author":"Stenberg","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011943.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/S1461145709990897","article-title":"Effects of add-on mirtazapine on neurocognition in schizophrenia: A double-blind, randomized, placebo-controlled study","volume":"13","author":"Stenberg","year":"2010","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD011943.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.schres.2010.02.674","article-title":"Effects of add-on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double-blind, randomized, placebo-controlled study, and both phases","volume":"117","author":"Stenberg","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0030|cit26","unstructured":"Terevnikov V Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia Dissertation 2013"},{"issue":"7","key":"10.1002\/14651858.CD011943.pub2-BIB0026|cit27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1017\/S146114571200137X","article-title":"Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial","volume":"16","author":"Terevnikov","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011943.pub2-BIB0027|cit28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hup.1189","article-title":"Add-on mirtazapine improves depressive symptoms in schizophrenia: A double-blind randomized placebo-controlled study with an open-label extension phase","volume":"26","author":"Terevnikov","year":"2011","journal-title":"Human Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD011943.pub2-BIB0028|cit29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hup.1137","article-title":"More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial","volume":"25","author":"Terevnikov","year":"2010","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0029|cit30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/08039488.2016.1233996","article-title":"Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics","volume":"71","author":"Terevnikov","year":"2017","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0031|cit31","unstructured":"Tereynikov V Joffe M Tiihonen J Stenberg J-H Burkin M Tchoukhine E More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain 2009"},{"issue":"2","key":"10.1002\/14651858.CD011943.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200403000-00003","article-title":"The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study","volume":"19","author":"Zoccali","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011943.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1043-6618(03)00178-6","article-title":"Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia","volume":"48","author":"Zoccali","year":"2003","journal-title":"Pharmacological Research"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0034|cit34","unstructured":"Geddes J Mirtazapine for schizophrenia Stanley Foundation Research Programs 2010"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0035|cit35","unstructured":"Geddes J Recovery: evaluation of mirtazapine and folic acid for schizophrenia http:\/\/www.controlled-trials.com 2010"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"22","author":"Addington","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD011943.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0038|cit38","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Andreasen NC Scale for the Assessment of Negative Symptoms: SANS Iowa: The University of Iowa 1981","DOI":"10.1037\/t12696-000"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0040|cit40","unstructured":"Andreasen NC Scale for the Assessment of Positive Symptoms: SAPS Iowa: the University of Iowa 1984"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0041|cit41","unstructured":"American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder 3rd edition psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf 2010"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011943.pub2-BIB0044|cit44","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0045|cit45","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal use report: optimal use of atypical antipsychotics for schizophrenia Canadian Agency for Drugs and Technologies in Health (CADTH) 2012 1 42"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011943.pub2-BIB0046|cit46","first-page":"89","article-title":"Clinical review of risperidone","volume":"38","author":"Chouinard","year":"1993","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1002\/hup.470100805","article-title":"The a2-selective adrenoreceptor antagonist Org 3770 (mirtazapine Remeron) enhances noradrenergic and serotonergic neurotransmission","volume":"10","author":"Boer","year":"1995","journal-title":"Human Psychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011943.pub2-BIB0048|cit48","first-page":"19","article-title":"The pharmacologic profile of mirtazapine","volume":"57","author":"Boer","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0049|cit49","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0050|cit50","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD011943.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0973-1229.91588","article-title":"Treatment-resistant schizophrenia: evidence-based strategies","volume":"10","author":"Englisch","year":"2012","journal-title":"Mens Sana Monographs"},{"issue":"7","key":"10.1002\/14651858.CD011943.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","article-title":"Impact of primary negative symptoms on functional outcomes in schizophrenia","volume":"29","author":"Fervaha","year":"2014","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis","volume":"303","author":"Fournier","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD011943.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011943.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/0272989X10375853","article-title":"Presenting the results of Cochrane systematic reviews to a consumer audience: a qualitative study","volume":"30","author":"Glenton","year":"2010","journal-title":"Medical Decision Making"},{"issue":"9","key":"10.1002\/14651858.CD011943.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0061|cit61","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised","author":"Guy","year":"1976"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD011943.pub2-BIB0062|cit62","first-page":"21","article-title":"Rating depressive patients","volume":"41","author":"Hamilton","year":"1980","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0063|cit63","first-page":"159","article-title":"Mirtazapine: a newer antidepressant","volume":"59","author":"Hartmann","year":"1999","journal-title":"American Family Physician"},{"issue":"7414","key":"10.1002\/14651858.CD011943.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0065|cit65","unstructured":"Higgins JP Green S Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0066|cit66","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1521\/psyc.2006.69.1.1","article-title":"A guide to the genetics of psychiatric disease","volume":"69","author":"Hough","year":"2006","journal-title":"Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD011943.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/JGP.0b013e3181d57441","article-title":"Successful aging in older adults with schizophrenia: prevalence and associated factors","volume":"18","author":"Ibrahim","year":"2010","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0264180100000904","article-title":"Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study","volume":"20","author":"Jablensky","year":"1992","journal-title":"Psychological Medicine Monograph Supplement"},{"issue":"6","key":"10.1002\/14651858.CD011943.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s004060070002","article-title":"Epidemiology of schizophrenia: the global burden of disease and disability","volume":"250","author":"Jablensky","year":"2002","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0001-6918(66)90004-7.","article-title":"The Stroop Color-Word Test: a review","volume":"25","author":"Jensen","year":"1966","journal-title":"Acta Psychologica"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0073|cit73","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD011943.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophrenia Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD011943.pub2-BIB0075|cit75","first-page":"194","article-title":"Atypical antipsychotic use in the treatment of psychosis in primary care","volume":"2","author":"Leo","year":"2000","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011943.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011943.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/schbul\/sbq016","article-title":"PANSS Should Be Rescaled","volume":"36","author":"Leucht","year":"2010","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011943.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review","volume":"39","author":"Marwaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0081|cit81","unstructured":"Mayo Clinic Drugs and supplements: mirtazapine (oral route) Mayo Clinic Site 2015"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiologic Reviews"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011943.pub2-BIB0083|cit83","first-page":"S7","article-title":"New directions in the epidemiology of schizophrenia","volume":"190","author":"McGrath","year":"2009","journal-title":"Medical Journal of Australia"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1749-6632.2001.tb05797.x","article-title":"Treatment of suicidality in schizophrenia","volume":"932","author":"Meltzer","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011943.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/00004850-199803003-00008","article-title":"Novel antipsychotics and negative symptoms","volume":"13","author":"Moller","year":"1998","journal-title":"International Clinical Psychopharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD011943.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","article-title":"Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review","volume":"88","author":"Murphy","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"10","key":"10.1002\/14651858.CD011943.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1592\/phco.31.10.1017","article-title":"Adjunct mirtazapine for negative symptoms of schizophrenia","volume":"31","author":"Phan","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD011943.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"Journal of Clinical and Experimental Neuropsychology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0090|cit90","volume-title":"The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation","author":"Reitan","year":"1985"},{"issue":"8","key":"10.1002\/14651858.CD011943.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","article-title":"CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Schulz","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0092|cit92","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD011943.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/oxfordjournals.schbul.a033490","article-title":"Distress attributed to negative symptoms in schizophrenia","volume":"26","author":"Selten","year":"2000","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD011943.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"issue":"1","key":"10.1002\/14651858.CD011943.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12888-014-0225-8","article-title":"Impact of negative symptoms on healthcare resource utilization and associated costs in adult out-patients with schizophrenia: a population-based study","volume":"14","author":"Sicras-Mainar","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0097|cit97","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1037\/h0054651","article-title":"Studies of interference in serial verbal reactions","volume":"18","author":"Stroop","year":"1935","journal-title":"Journal of Experimental Psychology"},{"issue":"5","key":"10.1002\/14651858.CD011943.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0100|cit100","volume-title":"Manual of Directions and Scoring","author":"Army Individual Test","year":"1944"},{"issue":"2","key":"10.1002\/14651858.CD011943.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.psychres.2008.10.009","article-title":"Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia","volume":"169","author":"Velligan","year":"2009","journal-title":"Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD011943.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3371\/CSRP.VIRE.030813","article-title":"Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia","volume":"9","author":"Vidal","year":"2015","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"issue":"4","key":"10.1002\/14651858.CD011943.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1037\/0033-295X.104.4.667","article-title":"Schizophrenia: a neural diathesis-stress model","volume":"104","author":"Walker","year":"1997","journal-title":"Psychological Review"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00223980.1945.9917223","article-title":"A standardized memory scale for clinical use","volume":"19","author":"Wechsler","year":"1945","journal-title":"Journal of Psychology"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0105|cit105","volume-title":"Wechsler Adult Intelligence Scale - Revised","author":"Wechsler","year":"1981"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0106|cit106","article-title":"Wechsler Memory Scales - Fourth Edition (WMS-IV): Administration and Scoring Manual","volume-title":"Wechsler Memory Scales - Fourth Edition (WMS-IV): Administration and Scoring Manual","author":"Wechsler","year":"2009"},{"key":"10.1002\/14651858.CD011943.pub2-BIB0107|cit107","unstructured":"World Health Organization Mental health: schizophrenia Retrieved from http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/ 2015"},{"issue":"7","key":"10.1002\/14651858.CD011943.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD011943.pub2-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011943","article-title":"Mirtazapine (adjunct) versus placebo for schizophrenia","author":"Stricklin","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011943.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:18:33Z","timestamp":1783394313000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011943.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,26]]},"references-count":109,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011943.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,26]]}}}